<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Georgoulias, V.</style></author><author><style face="normal" font="default" size="100%">Androulakis, N.</style></author><author><style face="normal" font="default" size="100%">Dimopoulos, A.M.</style></author><author><style face="normal" font="default" size="100%">Kourousis, C.</style></author><author><style face="normal" font="default" size="100%">Kakolyris, S.</style></author><author><style face="normal" font="default" size="100%">Papadakis, E.</style></author><author><style face="normal" font="default" size="100%">Apostolopoulou, F.</style></author><author><style face="normal" font="default" size="100%">Papadimitriou, C.</style></author><author><style face="normal" font="default" size="100%">Vossos, A.</style></author><author><style face="normal" font="default" size="100%">Agelidou, M.</style></author><author><style face="normal" font="default" size="100%">Heras, P.</style></author><author><style face="normal" font="default" size="100%">Tzannes, S.</style></author><author><style face="normal" font="default" size="100%">Vlachonicolis, J.</style></author><author><style face="normal" font="default" size="100%">Mavromanolakis, E.</style></author><author><style face="normal" font="default" size="100%">Hatzidaki, D.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">First-line treatment of advanced non-small-cell lung cancer with docetaxel and cisplatin: A multicenter phase II study</style></title><secondary-title><style face="normal" font="default" size="100%">Annals of Oncology</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Chemotherapy</style></keyword><keyword><style  face="normal" font="default" size="100%">Cisplatin</style></keyword><keyword><style  face="normal" font="default" size="100%">Docetaxel</style></keyword><keyword><style  face="normal" font="default" size="100%">Non-small-cell lung cancer</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">1998</style></year><pub-dates><date><style  face="normal" font="default" size="100%">1998</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-7144229342&amp;doi=10.1023%2fA%3a1008278103446&amp;partnerID=40&amp;md5=7fc4aa40fb857bcfc6952cdf942f2116</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">9</style></volume><pages><style face="normal" font="default" size="100%">331 - 334</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Purpose: To evaluate the efficacy and safety of the docetaxel-cisplatin combination in patients with advanced non-small-cell lung cancer (NSCLC). Patients and methods: Chemotherapy-naive patients with histologically confirmed, measurable stage IIIB or IV NSCLC, a World Health Organization (WHO) performance status of 0-2 and adequate bone marrow, renal, hepatic and cardiac function were eligible for the study. Patients received docetaxel (100 mg/m2) as an one-hour infusion on day 1 and cisplatin (80 mg/m2) as a 30-min infusion with appropriate hydration on day 2. Granulocyte colony- stimulating factor (G-CSF; 150 μg/m2, SC) was given on days 3 to 13. Treatment was repeated every three weeks. Results: Fifty-three patients were enrolled (28 with stage IIIB and 25 with stage IV). One complete and 23 partial responses were observed (overall response rate (OR): 45%; 95% CI: 34,1%-61.8%). The response rate was 57% and 32% in patients with stages IIIB and IV disease (P = NS). The median time to progression was 36 weeks and the median survival 48 weeks; the one-year survival was 48%. Grade 3-4 neutropenia occurred in 23 patients, 15 of whom were hospitalized for neutropenic fever; two patients died of sepsis. Grade 2 neurotoxicity was observed in six patients and grade 3 in five patients; grade 3 fatigue occurred in seven patients, grade 3-4 mucositis in four patients and grade 3- 4 diarrhea in six patients. Mild allergic reactions and oedema were observed in five and four patients, respectively. The median dose intensity was 30 mg/m2/week for docetaxel and 24 mg/m2/week for cisplatin, corresponding to 91% and 89% of the specified protocol doses, respectively. Conclusions: The docetaxel-cisplatin combination is an active regimen in advanced NSCLC, but hematologic toxicity remains high despite the prophylactic use of G-CSF.</style></abstract><issue><style face="normal" font="default" size="100%">3</style></issue><notes><style face="normal" font="default" size="100%">Cited By :70Export Date: 21 February 2017</style></notes></record></records></xml>